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In Vivo Targeting through Click Chemistry  
	  Yevgeny Brudno[1,2], Rajiv Desai[1,2], Brian J Kwee[1,2], Neel S Joshi[1,2], Michael Aizenberg[1], and David 
J Mooney[1,2,*] 
 
Abstract: Targeting small molecules to diseased tissues as therapy 
or diagnosis is a significant challenge in drug delivery. Drug-eluting 
devices implanted during invasive surgery allow for controlled 
presentation of drugs at disease site, but can not be modified once 
surgery is complete. We demonstrate that bioorthogonal click 
chemistry can be used to target circulating small molecules to 
hydrogels resident intramuscularly in diseased tissues. Additionally, 
we demonstrate that small molecules can repeatedly be targeted to 
the diseased area over the course of at least one month. Finally, two 
bioorthogonal reactions were used to segregate two small molecules 
injected as a mixture to two separate locations in a mouse disease 
model. These results demonstrate that click chemistry can be used 
for pharmacological drug delivery, and this concept is expected to 
have applications in refilling drug depots in cancer therapy, wound 
healing and drug-eluting vascular grafts and stents. 
Systemic drug toxicity is a serious problem in current clinical 
interventions, including in cancer, arrthymia[1], 
immunosuppression[2] and ocular[3] drug delivery. Local drug-
delivering devices confer a substantial reduction in toxicity and 
thus have significant clinical utility, including in prevention of 
restenosis with stenting[4], cancer treatment[5] and enhanced 
wound healing[6]. In applications where repeated local 
implantation of devices is not possible, such as for implantation 
of a drug-delivering scaffold during invasive surgery, drugs 
would need to be targeted to implant sites through non-invasive 
means. 
One approach to target implanted devices is to modify them with 
molecular targets capable of recognizing and binding small 
molecules circulating in the body. Accumulated small molecules 
bound by the implant could function in bound form, or be slowly 
released over time, allowing for controlled drug dosing. Here we 
report the utilization of bioorthogonal click chemistry to 
accumulate small molecules at a site of animal injury.  
Recently we introduced the concept of refillable drug delivery 
devices in which DNA recognition was used to target drug-
carrying nanoparticle refills to a device placed within a tumor 
site[7]. Drug payloads circulating in the blood of a patient could 
be bound by the device though specific chemical recognition, 
allowing for subsequent release through low-pH-mediated 
hydrolysis[8] or enzymatic degradation[9] at the target site.  
In this work we hypothesized that drug-eluting hydrogels could 
be targeted by small molecules in circulation through click 
chemistry-mediated recognition of the hydrogels. Two click 
chemistries were identified as candidates for drug targeting due 
to high specificity, efficient kinetics and established use in 
vivo[10]: 1) trans-cyclooctene (TCO) - Tetrazine (Tz) chemistry 
and 2) dibenzocyclooctyne (DBCO) - Azide (Az) chemistry. 
Alginate, a naturally occurring polysaccharide, was chosen as a 
drug delivery vehicle due to its clinical track record[1]. Alginate is 
biocompatible and non-immunogenic in intramuscular 
environments. Calcium carbonate-induced gelation of 
unoxidized, high MW alginate as used in this report creates 
nanoporous[2], injectable gels with a viscosity of .15-2 Pa*s[3].  
These gels present minimal changes in mass upon in vivo 
implantation[4] and present slow degradation kinetics in vivo, still 
present at implant site after multiple months[3, 5]. Further 
addition of click groups to alginate gels has not been noted to 
alter biocompatibility in vivo[6]. 
Alginate was modified with either tetrazine or azide through 
cabodiimide chemistry. NMR analysis demonstrated that on 
average 100 molecules of Tz/Az were attached to every alginate 
strand, constituting 400 nanomoles of target per mg of polymer.  
Specific binding of fluorescently-labeled TCO and DBCO 
molecules to hydrogels was established in vitro. Cy7-labeled 
trans-cyclooctene specifically bound to tetrazine-modified 
alginate, but not to unmodified alginate (Figure 1A). Similarly, 
fluorescent DBCO bound alginate-azide gels while 
demonstrating little interaction with unmodified alginate gels 
(Figure 1B). 
It was next investigated whether small molecules labeled with 
near-IR (NIR) fluorophores could target in vivo to gels resident at 
a disease site in an animal model of lower limb ischemia. 50 µL 
of tetrazine-modified, azide-modified, or unmodified alginate gels 
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Figure 1. Click chemistry-mediated gel targeting in vitro. (A) Azide-conjugated or 
control, calcium-crosslinked alginate gels were incubated with fluorophore 
carrying DBCO for 4 hours at 37°C. Retained fluorescence was quantified. (B) 
Tetrazine-conjugated or control, calcium-crosslinked alginate gels were 
incubated with fluorophore carrying trans-cyclooctene for 4 hours at 37°C. 
Retained fluorescence was quantified. 
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were implanted intra-muscularly in the limbs of mice subjected to 
femoral artery ligation, in a similar manner to the use of drug- 
delivering alginate gels to treat animal models of peripheral 
artery disease (PAD)[12]. 24-hours post-surgery, NIR-labeled 
DBCO or TCO-molecules were administered intravenously (IV) 
and the animals were monitored over 24 hours through live 
animal fluorescence imaging. We found that the NIR-labeled 
small molecules circulated in the animal’s system, and were 
eliminated mainly through the bladder in the first 24 hours (SI 
Figure 1), as expected[13]. After 24-hours, fluorescence was 
observed in the limbs implanted with modified gels, but not in 
control gels, which lacked the targeting motifs (Figure 2). 
To more accurately understand the dose of circulating molecules 
homing to intra-muscular gels, azide-modified gels were isolated 
from mouse muscles and digested. The amount of targeted 
molecules on the gels was quantified by fluorescence. An 
average of 106 picomoles of targeting compound, corresponding 
to 6.5% of the initially injected dose, localized to the intra-
muscular disease area (SI Table 1). This number of molecules 
constitutes only 0.03% of total available sites on the gel, 
suggesting that multiple gel fillings would be possible.  
Multiple intravascular administrations were then performed to 
repeatedly target and fill the intramuscular gel in injured mice. 
Mice with hind limb ischemia carrying azide-modified gels were 
repeatedly administered NIR-labeled DBCO, approximately once 
every three days for one month (Figure 3A). Over the one-month 
time course, limb fluorescence increased in a step-wise fashion, 
corresponding to fluorophore administrations (Figure 3B), with 
each dose increasing fluorescence to a similar extent (Figure 
3C). A small, but not significant, decrease in fluorescence in the 
limb was generally observed between 24- and 48-hours after IV 
injection, perhaps due to residual unbound fluorophore removed 
from the gel. 
It was hypothesized that the two molecules, DBCO and TCO, 
could selectively home to their respective binding partners to 
achieve spatial separation of drug-surrogates in the same 
animal. To test this, two sites on the mouse were chosen: 
tetrazine-modified gels were implanted intra-muscularly in the 
hind limb of mice subjected to hind-limb ischemia while azide-
modified gels were implanted into the mammary fat pad, to 
simulate a second target site. A mixture of Cy7-labeled DBCO 
and Cy5-labeled TCO was administered intravenously 24 hours 
after gel administration. Efficient targeting by the two small 
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Figure 2. Click-mediated targeting of a drug surrogate to hindlimb injury model. 
Mice subjected to hindlimb ischemia were implanted with unconjugated alginate 
gels or conjugated to azide (A-C) or tetrazine (D-F). Targeting to this gel was 
tested through IV injection of a fluorescently-labeled DBCO (A-C) or TCO (D-F). 
(A,C) reaction scheme (B,E) images and (C,F) quantification of fluorescence at 
the hind limb. Values represent mean and S.E.M. n=3. * represents p<.05 by 
Student's t-test. 
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Figure 3. Repeat targeting of fluorescent drug surrogates to intra-muscular gel. Fluorescently-labeled DBCO was repeatedly administered to mice (blue arrows) over the 
course of a one month. (A) Images and (B) quantitation of limb fluorescence 24 hours after repeat injections of targeting fluorescent DBCO. (C) Quantitation of 
fluorescence 24-hours after fluorophore administration shows a roughly linear increase in fluorescence with each injection. 
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molecules to their respective disease sites was observed (Figure 
4). Though targeting of hydrogels was previously 
demonstrated[10b], here we demonstrate gel homing within an 
animal model of ischemia. Additionally, we show repeated 
homing to the gel site over a period of one month and the ability 
to  segregate two different molecules through the use of two 
orthogonal chemistry systems. The ability to repeatedly target 
drug surrogates to a specific site within the body suggests that 
medical implants, such as hydrogels and medical devices, can 
be selectively targeted by small molecules circulating in the 
blood. 
The stability of tetrazines in serum is dependent on the precise 
chemical structure of tetrazine.  The tetrazine used in this report 
is reported to retain 40% function over ten hours[14], in 
agreement with the observation that intramuscular tetrazine-
modified gels could be filled 24 hours after implanatation, but 
failed to be targeted seven days after implantation. Future work 
can take advantage of more stable tetrazines for improved 
stability of targeted gels[14]. Additionally, the TCO and tetrazine 
groups could be exchanged in the drug targeting system, placing 
the more stable TCO group onto the long-lasting gel. These 
exciting possibilities are the subject of future work. 
Efficient and repeated targeting of drug depots could allow for 
long-lasting, local drug delivery at sites of intravascular stenting, 
intra-tumor chemotherapy delivery devices or surgical implants, 
allowing for lowered toxicity, improved dosing and drug 
availability at disease site. Efficient homing of drug molecules to 
sites defined by an implant could also allow for subsequent 
controlled or on-demand release by an external stimulus such as 
a magnetic field[15] or focused light[16]. 
In summary, we report a system for selective targeting of small 
molecule drug surrogates to hydrogels in both ischemic and 
non-ischemic locations, including in muscular and mammary 
sites. Click-mediated targeting exhibited a high degree of 
specificity for the target sites and the targeting could be 
repeated over a period of at least one month through nine 
administrations. Finally, we demonstrate spatial resolution of two 
different molecules targeting two different sites in the same 
animal, establishing the possibility to combine incompatible 
therapies in patients.  
Experimental Section 
For detailed experimental conditions and chemical analysis see the 
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Figure 4. Spatial encoding for two different small molecules. Alginate-Az gel was 
implanted intra-muscularly to mice with hind limb ischemia (left limb) and alginate-
Tz was implanted into the mammary fat pad (right body). A mixture of Cy5-TCO 
and Cy7-DBCO was injected IV and animals were imaged after 48 hours. (A) Cy5 
(red) and Cy7 (green) fluorescence shows homing of the respective click partners.  
(B) Quantification of fluorescence at implantation sites for both fluorophores. 
Values represent mean and S.E.M. n=3. * represents p<.01 by Student's t-test. 
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Selective targeting of small molecules to intramuscular and intradermal sites is achieved through click chemistry. Click-mediated 
targeting exhibited a high degree of specificity for the target sites and the targeting could be repeated over at least one month 
through nine administrations. Spatial resolution of two different molecules can be achieved by targeting them to two different sites in 
the same animal by use of orthogonal click chemistries,establishing the possibility of combining incompatible therapies in patients.  
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